Agitation in Delirium Management Market, By Drug Type (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines), By Route of Administration (Oral, Intramuscular, Others), By Distribution Channel (Hospital Pharmacies, Retail Phar

Delirium is a neurological condition which leads to disturbances in the mental abilities of a person. It causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as old age, exposure to certain medications, alcohol abuse, surgery or other medical procedures and factors such as exposure to toxic or infectious agents, physical trauma, diet, and other behavioral and occupational factors. There are two types of delirium: Hyperactive delirium and Hypoactive delirium. In hyperactive delirium, patients become overactive (agitation in delirium). Currently, market players are carrying out research and development activities for evaluating new medicines for the management of agitation in delirium among the patients.

Market Dynamics

Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients. For instance, in 2017, researchers at the University of California, San Diego, reported that sleep deprivation post-surgery causes delirium (confusion) in patients in the intensive care unit (ICU). Thus, they are conducting clinical trials for studying the role of Ramelteon, a medication that mimics the activity of melatonin (hormone which controls the body’s circadian rhythm or sleep – wake cycle) in improving the sleep quality, thus improving sleep quality is expected to help in preventing occurrence of delirium in the patients post open-heart surgery. The study is expected to be completed by December 1, 2021.

Market players are indulged in launching new first-generation antipsychotic drugs for the treatment of delirium, which is expected to spur the growth of the global agitation in delirium management market. For instance, in 2017, Lupin Limited launched Quetiapine Fumarate Extended-Release Tablets (50 mg, 150 mg, 200 mg, 300 mg and 400 mg strengths), after receiving approval from the U.S. Food and Drug Administration (U.S. FDA).

Key features of the study:

• This report provides an in-depth analysis of global agitation in delirium management market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global agitation in delirium management market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis International AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., and BioXcel Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the agitation in delirium management market

• Global Agitation in Delirium Management Market, By Drug:
• First-generation Antipsychotics
• Second-generation Antipsychotics
• Benzodiazepines
• Others
• Global Agitation in Delirium Management Market, By Route of Administration:
• Oral
• Intramuscular
• Others
• Global Agitation in Delirium Management Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Agitation in Delirium Management Market, By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Mylan N.V.
• Fresenius Kabi AG
• Novartis International AG
• Akorn Incorporated
• Zydus Cadila
• Pfizer, Inc.
• BioXcel Therapeutics, Inc.